Recent Updates
Recently added Catalysts
PFE Positive Sentiment

Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program

Wednesday, November 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Pfizer and Blackstone Life Sciences have entered a strategic funding agreement to co-develop berobenatide, a potential first-in-class GLP-1 receptor agonist for obesity management. Blackstone will contribute up to $1.5 billion for the development costs through 2028. This collaboration aims to address chronic weight management and related conditions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Pfizer and Blackstone collaborate on obesity treatment.
  • Funding agreement totals $1.5 billion through 2028.
  • Berobenatide may become a first-in-class treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+30%
120-day peak, hindsight
Typical move
1.3%
average across 15 past catalysts
Lead asset
CP-751,871+ carboplatin+ paclitaxel
Phase 2 · Prostatic Neoplasms

Full Press Release Details

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Blackstone Life Sciences (“Blackstone”) today announced a strategic co-funding agreement under which funds managed by Blackstone will pay up to a total of $1.5 billion of development costs through 2028 for berobenatide, an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions. In exchange for the funding, Blackstone will

Frequently Asked Questions

What is the funding amount for the obesity program?

The funding agreement totals up to $1.5 billion.

What is berobenatide being studied for?

Berobenatide is being studied for chronic weight management.

Who is co-funding the development costs?

Blackstone Life Sciences is co-funding the development costs.

What type of drug is berobenatide?

Berobenatide is a GLP-1 receptor agonist peptide.

ShareAdd on Google
Tags: PFE Pfizer Blackstone berobenatide obesity GLP-1 receptor agonist
Last updated: Nov 11, 2026

Biotech snapshot

Cash runway
$14272M liquidity · $0M/mo burn
Low dilution risk
Lead asset
CP-751,871+ carboplatin+ paclitaxelPhase 2
Prostatic Neoplasms →

Catalyst track record

+30%
best trade around PFE's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for PFE.

See every catalyst's timing & PoA →